Pharma’s China crack up

The headlines from Tuesday’s ethiXbase Monitor, a daily email of global corruption and compliance news, tell the story.

Here are the first four items:

China: Glaxo Executive Says Changes in China to Cut Drug Prices
Published on Jul 24, 2013 03:00 am
GlaxoSmithKline Plc (GSK)’s head of emerging markets said after meeting with government officials in Beijing some employees may have broken China’s laws and pledged corporate changes that will deliver cheaper medicines. . . .

China: GlaxoSmithKline To Detail Action Plan For Chinese Bribery Allegations On Wednesday
Published on Jul 24, 2013 02:00 am
Andrew Witty, chief executive of GlaxoSmithKline (LON:GSK), is to outline the actions the drugmaker is taking in response to allegations of bribery in China on Wednesday, when the company presents its quarterly results. . . .

China: China Travel Agency in Glaxo Probe Used by Sanofi, Roche
Published on Jul 24, 2013 01:00 am
Sanofi (SAN), Novartis AG, Merck (MRK) & Co. and Roche Holding AG worked with the same travel agency under investigation by Chinese authorities as part of a probe of GlaxoSmithKline Plc (GSK) over allegations of bribery and corruption. . .

China: AstraZeneca employee detained in China
Published on Jul 24, 2013 12:00 am
Officers from the Public Security Bureau are said to have detained an AstraZeneca employee after visiting the drug maker’s sales office in Citic Square, Shanghai, on Friday. . . .

The full version of Tuesday’s ethiXbase Monitor with links to the stories above can be viewed online here.

_____________

Richard L. Cassin is the Publisher and Editor of the FCPA Blog (a sister publication of the ethiXbase Monitor). He can be contacted here.